Professional development Vacancies

PREVENAR 13, pneumococcal polysaccharide conjugate vaccine, adsorbed, in a pre-filled syringe with a separate needle No. 1, Pfizer H.C.P. Corporation, USA

13.09.2024 Updated 18.11.2024 916 views
PREVENAR 13, pneumococcal polysaccharide conjugate vaccine, adsorbed, in a pre-filled syringe with a separate needle No. 1, Pfizer H.C.P. Corporation, USAPDF · 181 KB
Download PREVENAR 13, pneumococcal polysaccharide conjugate vaccine, adsorbed, in a pre-filled syringe with a separate needle No. 1, Pfizer H.C.P. Corporation, USA (PDF, 181 KB)Open in a new tab: PREVENAR 13, pneumococcal polysaccharide conjugate vaccine, adsorbed, in a pre-filled syringe with a separate needle No. 1, Pfizer H.C.P. Corporation, USA (PDF, 181 KB)

Other materials in this section

All 1 088 materials of the section
Useful resources
Conferences, Forums, Events
Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"
Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"
Forum "Clinical and preclinical studies in wartime: organization and development prospects"
Forum "Clinical and preclinical studies in wartime: organization and development prospects"
Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"
Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"
PHARMEXPERT 2024. Standards. Innovations. European integration
PHARMEXPERT 2024. Standards. Innovations. European integration
View all
Latest updates

Communication materials on the safe use of the medicinal product EYLEA® (aflibercept). Risk minimization in the use of the medicinal product
# For doctors # Pharmacovigilance # Letters — communications to medical and pharmaceutical professionals # 2026
Read more

Communication materials on the safe use of the medicinal product EYLEA® (aflibercept) for patients
# For patients # Pharmacovigilance # Letters — communications to patients # 2026
Read more

On the submission of periodic safety update reports (PSURs) using the new cover letter template
# For applicants # Pharmacovigilance # Frequency of submission of periodic safety update reports
Read more

Changes to the safety information of medicinal products containing aflibercept following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 06 – 09 July 2026
# For doctors # Pharmacovigilance # EMA # 2026
Read more

Changes to the safety information of medicinal products containing aflibercept following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 06 – 09 July 2026
# For applicants # Pharmacovigilance # EMA # 2026
Read more
All updates for today
Latest Announcements

Competitive selection of members of the HTA Expert Committee: deadline for submitting documents – until 12 October 2026

 More details

Updated! List of original (innovative) medicinal products registered in Ukraine as of 07.09.2026

 More details

Attention to business entities engaged in retail trade of medicinal products on the market of Ukraine! We provide lists of over-the-counter medicinal products by their storage conditions

 More details
All Announcements
Latest News
The Future of European Medicines Regulation: The State Expert Center Joins the 125th HMA Meeting in Dublin

The Future of European Medicines Regulation: The State Expert Center Joins the 125th HMA Meeting in Dublin

 More details
Unified Clinical Protocol for the Treatment of Bronchial Asthma in Adults Approved in Ukraine

Unified Clinical Protocol for the Treatment of Bronchial Asthma in Adults Approved in Ukraine

 More details
The Center recommends including the dual combination of umeclidinium bromide and vilanterol in the National List of Essential Medicines

The Center recommends including the dual combination of umeclidinium bromide and vilanterol in the National List of Essential Medicines 

 More details
All News